Generated by AI
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.
Website4 Kingsbury Avenue
Watertown, MA, 02472
United States
The latest articles about ENTA.
Detailed price information for Enanta Pharmaceutica (ENTA-Q) from The Globe and Mail including charting and trades.
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to...
Summary of Oct 1's posts. Generated by AI.
Summary of Sep 29's posts. Generated by AI.
Summary of Oct 1's posts. Generated by AI.
Summary of Sep 30's posts. Generated by AI.
Investors talking about ENTA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.